Presley et al. previously reported that broad‐based genomic sequencing was not associated with better survival than routine EGFR and/or ALK testing among advanced NSCLC patients receiving treatment in the community oncology setting.39 The gene discussed is ALK; the disease is non-small cell lung carcinoma.